 |
0 Diseases |  |
24 Trials |
|
24 Trials |  |
921 News |  |
| «12...4567891011121314...1920» |
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice (clinicaltrials.gov) - Aug 25, 2022
P=N/A, N=462, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting
- ||| Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk
Clinical: Thanks for your interest! I've tried both inj. and oral semaglutide in BAD patients with less luck. My hypothesis is that liraglutide has the perfect PK profile with an intermediate half-life and with peaks and troughs allowing adequate suppression of small intestinal motitlity. (Twitter) - Aug 22, 2022
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
RYBELSUS® CADA DESPERTAR, NUEVAS POSIBILIDADES ‼️ @novonordisk #semaglutideweightloss #diabeteschallenge #diabetesmellitus #diabetestipo2 #semaglutida #semaglutide #obesidad #Rybelsus #diabetes (Twitter) - Aug 19, 2022
- || Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal: PIONEER START: Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity (clinicaltrials.gov) - Aug 16, 2022
P3, N=0, Withdrawn, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting N=600 --> 0 | Trial completion date: Aug 2026 --> Aug 2025 | Initiation date: Jul 2023 --> Jul 2022 | Not yet recruiting --> Withdrawn
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial, Real-world evidence, Real-world: PIONEER REAL: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India (clinicaltrials.gov) - Aug 16, 2022
P=N/A, N=388, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Journal: Cardiovascular effects of incretins - focus on GLP-1 receptor agonists. (Pubmed Central) - Aug 5, 2022
Liraglutide, oral semaglutide and exenatide once weekly also reduced mortality...In the 2019 consensus report from EASD/ADA, GLP-1 RAs with demonstrated cardio-renal benefits (liraglutide, semaglutide and dulaglutide) are recommended after metformin to patients with established cardiovascular diseases or multiple cardiovascular risk factors...However, the results from cardiovascular outcome trials (CVOT) are very heterogeneous suggesting that some GLP-1RA are more suitable to prevent CVD than others. The CVOTs provide a basis upon which individual treatment decisions for patients with T2D and CVD can be made.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date: A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity (clinicaltrials.gov) - Aug 5, 2022
P1, N=60, Recruiting, Sponsor: Novo Nordisk A/S
The CVOTs provide a basis upon which individual treatment decisions for patients with T2D and CVD can be made. Trial primary completion date: Jun 2022 --> Nov 2022
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial initiation date, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice (clinicaltrials.gov) - Jul 29, 2022
P=N/A, N=194, Not yet recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Jun 2022 --> Nov 2022 Initiation date: Jul 2022 --> Oct 2022
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion date, Trial initiation date, Trial primary completion date: PIONEER START: Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity (clinicaltrials.gov) - Jul 29, 2022
P3, N=600, Not yet recruiting, Sponsor: Novo Nordisk A/S
Initiation date: Jul 2022 --> Oct 2022 Trial completion date: Aug 2025 --> Aug 2026 | Initiation date: Jul 2022 --> Jul 2023 | Trial primary completion date: Oct 2023 --> Oct 2024
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open, Trial primary completion date, Real-world evidence, Real-world: NN9924-4645: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice (clinicaltrials.gov) - Jul 29, 2022
P=N/A, N=194, Recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Aug 2025 --> Aug 2026 | Initiation date: Jul 2022 --> Jul 2023 | Trial primary completion date: Oct 2023 --> Oct 2024 Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2023 --> Jul 2023
- | Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Design and Development of a New Glucagon-Like Peptide-1 Receptor Agonist to Obtain High Oral Bioavailability. (Pubmed Central) - Jul 29, 2022
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2023 --> Jul 2023 We believe that the design and development of oral SHR-2042 will provide a new way to design more and more GLP-1RAs with high oral bioavailability in the future.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Review, Journal: A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form. (Pubmed Central) - Jul 27, 2022
The evolution of the GLP-1RA class to include an oral pill will facilitate the use of this class of agents much earlier in the diabetes treatment cascade owing to wider acceptance from patients and clinicians alike. The current review discusses the various aspects of oral semaglutide and its place in clinical practice.
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (clinicaltrials.gov) - Jul 25, 2022
P=N/A, N=462, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Effects of Semaglutide on Stroke Subtypes in DM2: #SUSTAIN 6 & #PIONEER 6 👉 (Twitter) - Jul 25, 2022
- || Rybelsus (semaglutide oral) / Novo Nordisk
Review, Journal: New Hypoglycemic Drugs: Combination Drugs and Targets Discovery. (Pubmed Central) - Jul 23, 2022
With the widespread clinical application of oral semaglutide, it is time to develop combinations drugs containing new hypoglycemic drugs, especially SGLT-2i and/or GLP-1RA, to control the risk of prediabetes and newly diagnosed T2DM and its cardiovascular complications, while improving patient compliance...How this comprehensive protective effect regulates the dynamic changes of heart genes needs further study. We provide ideas for the development of heart failure drugs from the perspective of "clinical drug-mechanism-intensive disease treatment." This will help to accelerate the development of heart failure drugs, and to some extent guide the use of heart failure drugs.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (clinicaltrials.gov) - Jul 23, 2022
P=N/A, N=194, Active, not recruiting, Sponsor: Novo Nordisk A/S
We provide ideas for the development of heart failure drugs from the perspective of "clinical drug-mechanism-intensive disease treatment." This will help to accelerate the development of heart failure drugs, and to some extent guide the use of heart failure drugs. Trial primary completion date: Jul 2022 --> Dec 2022
- Rybelsus (semaglutide oral) / Novo Nordisk
Investigating neuroprotective effects of semaglutide in early Alzheimer's disease: trial designs for evoke and evoke+ (A1) - Jul 18, 2022 - Abstract #EAN2022EAN_1435;
P3
Patients will be randomised 1:1 to once-daily oral semaglutide 14 mg or placebo, added to standard of care, for 104 weeks plus a 52-week extension... The evoke and evoke+ trials will investigate the neuroprotective effects of semaglutide in early AD with and without CSVD.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion date, Trial primary completion date, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice (clinicaltrials.gov) - Jul 15, 2022
P=N/A, N=194, Enrolling by invitation, Sponsor: Novo Nordisk A/S
The evoke and evoke+ trials will investigate the neuroprotective effects of semaglutide in early AD with and without CSVD. Trial completion date: Sep 2022 --> Feb 2023 | Trial primary completion date: Apr 2022 --> Feb 2023
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study. (Pubmed Central) - Jul 14, 2022
Most adverse events were grade 1-2 transient gastrointestinal disorders. Oral semaglutide treatment in patients with NAFLD complicated by T2DM improved impaired liver function, hypertriglyceridemia, insulin resistance, and hepatic steatosis, as well as improving diabetic status and reducing body weight.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Retrospective data, Review, Journal: The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis. (Pubmed Central) - Jul 13, 2022
It was superior to subcutaneous semaglutide and inferior to other GLP-1 RA comparators and placebo in terms of the incidence of adverse events. Thus, oral semaglutide provides a convenient administration route for patients who prefer oral treatments over injectable therapies.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk, dapagliflozin/semaglutide (NN9917) / Novo Nordisk
Enrollment open: A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet (clinicaltrials.gov) - Jul 13, 2022
P1, N=138, Recruiting, Sponsor: Novo Nordisk A/S
Thus, oral semaglutide provides a convenient administration route for patients who prefer oral treatments over injectable therapies. Not yet recruiting --> Recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Higher adherence and persistence for dulaglutide compared to oral semaglutide at 6- months follow-up with U.S. real-world data (Short Oral Discussion Area) - Jul 9, 2022 - Abstract #EASD2022EASD_1312;
Not yet recruiting --> Recruiting During the 6-mo follow-up period, DU patients had significantly higher adherence and persistence compared to OS patients.
- Rybelsus (semaglutide oral) / Novo Nordisk
Multifactorial risk reduction with oral semaglutide vs comparators in the treatment of type 2 diabetes (Short Oral Discussion Area) - Jul 9, 2022 - Abstract #EASD2022EASD_1004;
P3
Multifactorial risk factor management is fundamental to long-term risk reduction in patients with T2D. Oral semaglutide was more effective at improving multiple cardiometabolic risk factors vs comparators, indicating its potential to help address the full cardiometabolic profile for patients with T2D.
- Rybelsus (semaglutide oral) / Novo Nordisk
Greater time spent in glycaemic control with oral semaglutide vs oral comparators (Short Oral Discussion Area) - Jul 9, 2022 - Abstract #EASD2022EASD_774;
P3
In PIONEER trials of ≥52 weeks, oral semaglutide resulted in greater time spent at glycaemic target and a greater likelihood of maintaining glycaemic control vs oral comparators. Patients receiving oral semaglutide spent a similar time in glycaemic control vs liraglutide, despite a longer dose-escalation with oral semaglutide.
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Effect of semaglutide versus placebo on cardiovascular outcomes by baseline HbA 1c : SUSTAIN 6 and PIONEER 6 post hoc analysis (Short Oral Discussion Area) - Jul 9, 2022 - Abstract #EASD2022EASD_771;
P3
The effect of semaglutide vs placebo on MACE and its components was consistent across baseline HbA 1c in the SUSTAIN 6 and PIONEER 6 pooled T2D population. These data indicate that the beneficial CV effect of semaglutide is consistent regardless of HbA 1c values.
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Effect of semaglutide on MACE by baseline kidney function in participants with type 2 diabetes and high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc analysis (Minkowski Hall) - Jul 9, 2022 - Abstract #EASD2022EASD_302;
P3
Semaglutide showed consistent reductions in MACE risk across eGFR and UACR subgroups. These findings indicate that semaglutide provides CV benefits in people with T2D and high CV risk across a broad spectrum of kidney function and damage.
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P4 trial: OSO: Efficacy of Oral Semaglutide in Overweight or Obesity (clinicaltrials.gov) - Jul 4, 2022
P4, N=116, Recruiting, Sponsor: Asian Institute of Gastroenterology, India
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice (clinicaltrials.gov) - Jul 4, 2022
P=N/A, N=194, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice (clinicaltrials.gov) - Jul 4, 2022
P=N/A, N=462, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice (clinicaltrials.gov) - Jul 4, 2022
P=N/A, N=194, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk
New P3 trial: PIONEER START: Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity (clinicaltrials.gov) - Jul 4, 2022
P3, N=600, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Semaglutide Rybelsus Ozempic Wegovy Confusion: All contain same active drug, Rybelsus is oral tablet, Ozempic is subcutaneous injection, both for lowering A1c in DM. Wegovy is for weight loss, also an injection, but the dose is much higher than Ozempic. https://t.co/lXtPL4A81V (Twitter) - Jul 4, 2022
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal, HEOR: The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials. (Pubmed Central) - Jul 1, 2022
These findings indicate that semaglutide provides CV benefits in people with T2D and high CV risk across a broad spectrum of kidney function and damage. Oral semaglutide 14 mg was dominant versus sitagliptin and liraglutide, and cost-effective versus empagliflozin, for the treatment of type 2 diabetes in Spain.
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
New P4 trial: ASCEND PLUS: A Study of Cardiovascular Events iN Diabetes Plus (clinicaltrials.gov) - Jul 1, 2022
P4, N=20000, Not yet recruiting, Sponsor: University of Oxford
- || Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Retrospective data, Review, Journal: Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes. (Pubmed Central) - Jun 29, 2022
Tirzepatide, oral and SC semaglutide has a favourable efficacy in treating T2DM. The adverse events were comparable to placebo; however, gastrointestinal adverse events were highly recorded in tirzepatide, oral and SC semaglutide groups.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Review, Journal: The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs. (Pubmed Central) - Jun 29, 2022
Currently, there is no data available on oral semaglutide in Indian clinical settings. However, significant improvements in glycemic control, cardiac and renal benefits, as well as weight loss across clinical trials should encourage clinicians to prioritize oral semaglutide over other antidiabetic agents.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk, dapagliflozin/semaglutide (NN9917) / Novo Nordisk
New P1 trial: A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet (clinicaltrials.gov) - Jun 23, 2022
P1, N=138, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || Januvia (sitagliptin) / Merck (MSD)
Trial initiation date: Semaglutide vs Sitagliptin (clinicaltrials.gov) - Jun 16, 2022
P4, N=140, Not yet recruiting, Sponsor: University Health Network, Toronto
However, significant improvements in glycemic control, cardiac and renal benefits, as well as weight loss across clinical trials should encourage clinicians to prioritize oral semaglutide over other antidiabetic agents. Initiation date: Apr 2022 --> Aug 2022
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice (clinicaltrials.gov) - Jun 13, 2022
P=N/A, N=462, Recruiting, Sponsor: Novo Nordisk A/S
Initiation date: Apr 2022 --> Aug 2022 Not yet recruiting --> Recruiting
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
P3 data, Journal: Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme. (Pubmed Central) - Jun 9, 2022
Not yet recruiting --> Recruiting Oral semaglutide demonstrated consistently greater HbA1c and body weight reductions across a range of patient characteristics, with greater HbA1c reductions seen at higher baseline HbA1c levels.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice (clinicaltrials.gov) - Jun 8, 2022
P=N/A, N=194, Recruiting, Sponsor: Novo Nordisk A/S
Oral semaglutide demonstrated consistently greater HbA1c and body weight reductions across a range of patient characteristics, with greater HbA1c reductions seen at higher baseline HbA1c levels. Not yet recruiting --> Recruiting
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Cambios en composición corporal con Semaglutide 2.4 en #obesidad #ADA2022 @Diabetes_SEMI (Twitter) - Jun 6, 2022
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials. (Pubmed Central) - Jun 4, 2022
Not yet recruiting --> Recruiting Oral semaglutide is effective across a range of baseline subgroups of Japanese patients with type 2 diabetes, with no unexpected safety findings.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Clinical protocol, Journal: Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study). (Pubmed Central) - May 26, 2022
020-013). UMIN000045270 in the University Hospital Medical Information Network; jRCT1011210032 in the Japan Registry of Clinical Trials.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Couldn’t oral semaglutide be administered under the tongue for better absorption? (Twitter) - May 25, 2022
- || Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: @tmodarressi - Couldn't patients administer Rybelsus sublingually daily for effectively the same approximate dose of Semiglutide (vs Wegovy)? (Twitter) - May 25, 2022
- | Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: SAMAS: Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients (clinicaltrials.gov) - May 23, 2022
P=N/A, N=100, Recruiting, Sponsor: University Medical Centre Ljubljana
UMIN000045270 in the University Hospital Medical Information Network; jRCT1011210032 in the Japan Registry of Clinical Trials. Not yet recruiting --> Recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk
Semaglutide Tolerability and Efficacy in Patients with Chronic Kidney Disease Stage 4, 5 and End Stage Renal Disease (Hynes Halls C & D: Board No. A194) - May 20, 2022 - Abstract #ATC2022ATC_3258;
Semaglutide can be safely used in this patient population with modest weight loss and improvement in diabetic parameters. However, more studies in larger populations are needed to better determine the risks and benefits and guide appropriate use of this medication, either independently or in conjunction with bariatric surgery.
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk. (Pubmed Central) - May 18, 2022
Adding semaglutide to SoC was associated with a gain in life-years free of CVD events that was dependent on baseline CVD risk and age at treatment initiation. This study helps contextualize the results of semaglutide clinical trials.
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: In brief: Higher-dose semaglutide (Ozempic) for type 2 diabetes. (Pubmed Central) - May 18, 2022
This study helps contextualize the results of semaglutide clinical trials. No abstract available